Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 16, 2023
Subject: Announcement of a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of Jemperli (dostarlimab) in combination with chemotherapy for a new frontline treatment indication.
Key Financial Metrics
This filing is a regulatory update regarding clinical trial outcomes and regulatory progress. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial metric.
Material Changes and Clinical Data
The filing details significant clinical trial results from the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III trial (Part 1) regarding the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer:
- Progression-Free Survival (PFS): A 72% reduction in the risk of disease progression or death was observed with dostarlimab plus chemotherapy compared to chemotherapy alone (Hazard Ratio: 0.28).
- Overall Survival (OS): An exploratory analysis showed a 70% reduction in the risk of death (Hazard Ratio: 0.30).
- Regulatory Status: The CHMP has adopted a positive opinion. A final marketing authorisation decision by the European Commission is expected by the end of 2023.
- Global Context: This indication was previously approved in the US (July 2023) and the UK (October 2023). Applications remain under review in Australia, Canada, Switzerland, and Singapore.
Outlook, Risks, and Management Commentary
Management Commentary: Hesham Abdullah, Senior Vice President of Global Head Oncology, R&D, stated that if approved, this combination would be the first new frontline treatment option in the EU in decades for this patient population, offering improved long-term outcomes.
Outlook:
- Decision on EU marketing authorisation expected by the end of 2023.
- Current conditional approval for Jemperli monotherapy in the EU is expected to convert to full approval upon the approval of the new frontline indication.
Risks and Contingencies:
- Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
- Specific risks include those described in the company's Annual Report on Form 20-F for 2022 and Q2 Results for 2023.
- Continued approval for certain solid tumour indications in the US may be contingent upon verification of clinical benefit in confirmatory trials.
Investor Verification Checklist
- Confirm the final marketing authorisation decision by the European Commission by the end of 2023.
- Monitor the conversion of the current conditional EU approval to full approval.
- Track regulatory decisions in Australia, Canada, Switzerland, and Singapore.
- Review the full safety profile and adverse events listed in the EMA Reference Information.
- Assess the commercial impact of this new indication on GSK's oncology portfolio relative to the estimated 3,000 annual diagnoses in the EU4.